Tag Archives: DNA

Update, Partner and Innovate — AUTM Eastern Regional Meeting

Posted on April 14, 2011 by Warren Woessner

I will be on a panel entitled “Kicking the Hornet’s Nest – Patenting Early Stage Technology” at the AUTM Eastern Regional Meeting in Baltimore (May 24th). I will be joined by Esther Kepplinger, Director of Patent Operations at Wilson Sonsini … Continue reading →

Posted in Conferences and Classes | Tagged Ariad v. Lilly, AUTM, DNA, Patent Law, Warren Woessner | Leave a comment

Myriad Oral Arguments – Section 101 vs. Chemistry 101?

Posted on April 8, 2011 by Warren Woessner

After listening to the IPO webinar and reading the detailed account by Kevin Noonan in PatentDocs on the Myriad oral arguments, I was somewhat heartened to “hear” the Fed. Cir. panel moving toward “getting it” regarding what an isolated DNA … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged DNA, Federal Circuit, intellectual property, Patent Law, Warren Woessner | 2 Comments

Federal Court Hears Myriad Gene Case This Morning

Posted on April 5, 2011 by Warren Woessner

The following is a guest post from Ann McCrackin. I attended oral arguments at the CAFC on Monday for Association for Molecular Pathology v. Myriad Genetics, Inc. The three-judge panel included Judge Bryson, Judge Lourie and Judge Moore. Most of the … Continue reading →

Posted in Burden of Proof | Tagged Ann McCrackin, biotechnology, biotechnology law, biotechnology news, cafc, DNA, Federal Circuit, intellectual property, ip, IP law tools, Myriad, Myriad lawsuit, Patent Law, patents, RCT v. Microsoft, USPTO, Warren Woessner | Leave a comment

ACLU Files Its Brief in Myriad – Argues DNA Is A Blueprint Without a Name

Posted on January 28, 2011 by Warren Woessner

On November 30, 2010, the ACLU filed its brief at the Federal Circuit in AMP et al. v. USPTO and Myriad Genetics, Inc. et al. If you have been reading my posts on this suit, you are by now probably … Continue reading →